DrugPatentWatch Database Preview
Drugs in Development Information for GS-4997
» See Plans and Pricing
What is the drug development status for GS-4997?
GS-4997 is an investigational drug.
There have been 9 clinical trials for GS-4997.
The most recent clinical trial was a Phase 2 trial, which was initiated on January 30th 2017.
The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Fatty Liver, and Diabetic Nephropathies. The leading clinical trial sponsors are Gilead Sciences, HepQuant, LLC, and [disabled in preview].
There are twelve US patents protecting this investigational drug and one hundred and seventy-nine international patents.
Summary for GS-4997
| US Patents | 12 |
| International Patents | 179 |
| US Patent Applications | 20 |
| WIPO Patent Applications | 13 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2017-01-30) |
| Vendors | 42 |
Recent Clinical Trials for GS-4997
| Title | Sponsor | Phase |
|---|---|---|
| Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis | Gilead Sciences | Phase 3 |
| Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) | Gilead Sciences | Phase 3 |
| GS-4997 in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH) | Gilead Sciences | Phase 2 |
Clinical Trial Summary for GS-4997
Top disease conditions for GS-4997
Top clinical trial sponsors for GS-4997
US Patents for GS-4997
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| GS-4997 | Start Trial | Methods of treating liver disease | Gilead Sciences, Inc. (Foster City, CA) | Start Trial |
| GS-4997 | Start Trial | Cyclobutyl-imidazolidinone compounds | ELI LILLY AND COMPANY (Indianapolis, IN) | Start Trial |
| GS-4997 | Start Trial | Apoptosis signal-regulating kinase inhibitors | Gilead Sciences, Inc. (Foster City, CA) | Start Trial |
| GS-4997 | Start Trial | Apoptosis signal-regulating kinase inhibitor | Gilead Sciences, Inc. (Foster City, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for GS-4997
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| GS-4997 | Australia | 2015320792 | 2034-09-24 | Start Trial |
| GS-4997 | Australia | 2018271289 | 2034-09-24 | Start Trial |
| GS-4997 | Brazil | 112017005693 | 2034-09-24 | Start Trial |
| GS-4997 | Canada | 2962572 | 2034-09-24 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
